Advances in cancer research最新文献

Liquid biopsy in early detection and monitoring of CNS metastases. 液体活检在早期发现和监测中枢神经系统转移中的作用。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-21 DOI: 10.1016/bs.acr.2025.04.007

Natasha Hongsermeier-Graves, Mohammed Hasen, Noah Yaffe, Andrew Ajisebutu, Rachna Malani

引用次数: 0

Molecular drivers in CNS metastatic disease. 中枢神经系统转移性疾病的分子驱动因素。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-30 DOI: 10.1016/bs.acr.2025.04.004

Hannah Kim, Sofia Chernet, Priya Kumthekar, Akanksha Sharma

引用次数: 0

Advances in minimally invasive surgery for brain metastases. 微创手术治疗脑转移瘤的进展。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-08 DOI: 10.1016/bs.acr.2025.04.003

Nicole A Perez, Bryan D Choi, Brian V Nahed

{"title":"Advances in minimally invasive surgery for brain metastases.","authors":"Nicole A Perez, Bryan D Choi, Brian V Nahed","doi":"10.1016/bs.acr.2025.04.003","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.04.003","url":null,"abstract":"Brain metastases (BMs) affect approximately 10-30 % of cancer patients, and their prevalence is growing as patients live longer with controlled primary disease. Surgical resection remains a cornerstone of treatment for both solitary and multifocal lesions. Since the advent of intracranial tumor surgery, neurosurgery has trended towards less invasive surgical approaches, facilitated by a proliferation of surgical innovations ranging from intraoperative MRI to tubular retractors. Minimally invasive cranial surgery (MICS) incorporates approaches such as keyhole craniotomies and tubular retraction with the goal of maximizing extent of resection and reducing iatrogenic tissue injury. Supramarginal resection builds upon this approach, expanding the boundaries of the resection cavity to ensure removal of microscopic tumor fragments and decrease recurrence. Because MICS is generally performed through craniotomies< 5 cm in diameter with limited ability to change predefined surgical corridors intraoperatively, meticulous attention must be given to the preoperative workup. Imaging modalities, including CT, MRI, DWI, and DTI, may reveal characteristics of the intra-tumoral environment and are important in defining the anatomical relationship of BMs to surrounding functional tissue and neurovascular structures. Intraoperatively, neuronavigation helps maintain alignment within predefined surgical corridors, and adjunctive modalities such as intraoperative ultrasound and brain mapping help compensate for brain shift. Advancements in visual augmentation tools such as fluorescence, endoscopes, and exoscopes further enable intraoperative delineation of tumor boundaries and allow for expanded utilization of MICS in deep-seated, complex BMs. The ever-growing armamentarium of minimally invasive surgical tools has made neurosurgery an increasingly safe and effective option for patients with BMs.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"165-230"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision medicine approaches to CNS metastatic disease. 精准医学方法治疗中枢神经系统转移性疾病。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-14 DOI: 10.1016/bs.acr.2025.04.005

Toni Cao, Meaghan Roy-O'Reilly, Seema Nagpal

{"title":"Precision medicine approaches to CNS metastatic disease.","authors":"Toni Cao, Meaghan Roy-O'Reilly, Seema Nagpal","doi":"10.1016/bs.acr.2025.04.005","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.04.005","url":null,"abstract":"Brain metastases (BrM) and leptomeningeal metastases (LM) are increasingly common neurologic complications of cancer. The era of precision oncology has ushered in a deeper understanding of the molecular alterations that drive oncogenesis, subsequently informing and accelerating the drug development process. New systemic treatments, including oral tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs) as well as antibody-drug conjugates (ADCs), have substantial intracranial efficacy with meaningful clinical benefit for BrM patients. Our understanding of LM continues to evolve with the development of improved detection methods and an increasing number of brain penetrant therapies. Targeted therapeutics continue to transform the existing treatment landscape and add both choice and complexity to the clinician's calculus when managing patients with BrM and/or LM. Multidisciplinary discussion should ultimately guide all treatment decisions and explore both the benefits and toxicities of various therapy options. Systemic targeted therapies should be considered for patients with asymptomatic or minimally symptomatic small BrM and/or LM. Future studies investigating treatment timing and effective combinatorial strategies are urgently needed.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"57-114"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation therapy for cerebral metastases: Non-stereotactic treatment options. 脑转移瘤的放射治疗：非立体定向治疗选择。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-21 DOI: 10.1016/bs.acr.2025.04.008

John G Roubil, Timothy J Harris

引用次数: 0

Stereotactic radiosurgery for brain metastases. 立体定向放射外科治疗脑转移瘤。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-24 DOI: 10.1016/bs.acr.2025.04.001

Stylianos Pikis, Maria Protopapa, Georgios Mantziaris, Mahmoud Osama, Jason Sheehan

{"title":"Stereotactic radiosurgery for brain metastases.","authors":"Stylianos Pikis, Maria Protopapa, Georgios Mantziaris, Mahmoud Osama, Jason Sheehan","doi":"10.1016/bs.acr.2025.04.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.04.001","url":null,"abstract":"Brain metastases are the most common intracranial malignancies in adults, and, depending on primary tumor type, they may affect up to 50 % of cancer patients. Although advances in systemic and local therapies have led to improvements in patient overall survival and progression free survival, there remains substantial opportunities to improve patient outcomes. Stereotactic radiosurgery (SRS) delivers high doses of ionizing radiation with sub-millimeter accuracy to discrete intracranial tumors. It has emerged as the standard of care for patients with limited number of brain metastases, and it serves as a valuable adjuvant after resection. Moreover, SRS is typically seamlessly integrated into systemic therapy treatment regimens. Continued improvement in SRS technology and growing evidence have led to expansion of SRS indications and introduction of new SRS techniques. Frameless SRS technologies have allowed for treatment of larger lesions and even lesions adjacent to critical structures for which single session SRS would not be prudent. Neoadjuvant SRS has recently been proposed as an alternative to adjuvant SRS and appears to help reduce the risk of leptomeningeal dissemination. These novel SRS techniques require further evaluation through prospective clinical trials and registry based studies. In addition, the concurrent combination of systemic therapies with central nervous system (CNS) activity and SRS has yielded promising results with respect to local control and adverse radiation events rates. The concurrent delivery of SRS, precision medicine, and/or immunotherapy requires further refinements to fully optimize patient outcomes. In this review, we detail the current literature on established and forthcoming indications of SRS for brain metastases.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"115-143"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The history of LITT for the treatment of active brain metastasis and radiation necrosis. LITT治疗活动性脑转移和放射性坏死的历史。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-08 DOI: 10.1016/bs.acr.2025.04.002

Theresa Gammel, Shawn D'Souza, William Broaddus

引用次数: 0

Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy. 推进癌症治疗：整合可扩展的三维癌症模型、细胞外囊泡和 omics，提高疗效。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-20 DOI: 10.1016/bs.acr.2024.07.001

Pedro P Gonçalves, Cláudia L da Silva, Nuno Bernardes

{"title":"Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy.","authors":"Pedro P Gonçalves, Cláudia L da Silva, Nuno Bernardes","doi":"10.1016/bs.acr.2024.07.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.07.001","url":null,"abstract":"Cancer remains as one of the highest challenges to human health. However, anticancer drugs exhibit one of the highest attrition rates compared to other therapeutic interventions. In part, this can be attributed to a prevalent use of in vitro models with limited recapitulative potential of the in vivo settings. Three dimensional (3D) models, such as tumor spheroids and organoids, offer many research opportunities to address the urgent need in developing models capable to more accurately mimic cancer biology and drug resistance profiles. However, their wide adoption in high-throughput pre-clinical studies is dependent on scalable manufacturing to support large-scale therapeutic drug screenings and multi-omic approaches for their comprehensive cellular and molecular characterization. Extracellular vesicles (EVs), which have been emerging as promising drug delivery systems (DDS), stand to significantly benefit from such screenings conducted in realistic cancer models. Furthermore, the integration of these nanomedicines with 3D cancer models and omics profiling holds the potential to deepen our understanding of EV-mediated anticancer effects. In this chapter, we provide an overview of the existing 3D models used in cancer research, namely spheroids and organoids, the innovations in their scalable production and discuss how omics can facilitate the implementation of these models at different stages of drug testing. We also explore how EVs can advance drug delivery in cancer therapies and how the synergy between 3D cancer models and omics approaches can benefit in this process.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"163 ","pages":"137-185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial metallopeptidase OMA1 in cancer. 癌症中的线粒体金属肽酶 OMA1

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.1016/bs.acr.2024.05.001

Gunjan Purohit, Polash Ghosh, Oleh Khalimonchuk

引用次数: 0

Deciphering the genetic and epigenetic architecture of prostate cancer. 解密前列腺癌的基因和表观遗传结构。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-22 DOI: 10.1016/bs.acr.2024.06.001

Sheeraz Un Nazir, Juhi Mishra, Shailendra Kumar Maurya, Negin Ziamiavaghi, Sanika Bodas, Benjamin A Teply, Samikshan Dutta, Kaustubh Datta

{"title":"Deciphering the genetic and epigenetic architecture of prostate cancer.","authors":"Sheeraz Un Nazir, Juhi Mishra, Shailendra Kumar Maurya, Negin Ziamiavaghi, Sanika Bodas, Benjamin A Teply, Samikshan Dutta, Kaustubh Datta","doi":"10.1016/bs.acr.2024.06.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.06.001","url":null,"abstract":"Prostate cancer, one of the most frequently diagnosed cancers in men, leads to significant mortality worldwide. Its study is important due to the complexity and diversity in its progression, highlighting the urgent need for improved therapeutic strategies. This chapter probes into the genetic and epigenetic factors influencing prostate cancer progression, underscoring the importance of understanding the disease's molecular fundamentals for the development of targeted therapies. It specifically reviews the role of key genetic mutations in genes such as Androgen Receptor, TP53, SPOP, FOXA1 and PTEN which are crucial for the disease onset and a progression. Furthermore, it examines the impact of epigenetic modifications, including DNA methylation and histone modification, which contribute to the cancer's progression by affecting gene expression and cellular behavior. Further, in this chapter we delve into the underlying signaling mechanism, the advancements in targeting genetic and epigenetic alterations in prostate cancer. These findings have revealed promising targets for therapeutic advancements, aiming to understand and identify promising avenues for future therapies. This chapter improves our current understanding of prostate cancer genetic and epigenetic landscape, emphasizing the necessity of advancing our knowledge to refine and expand treatment options for prostate cancer patients.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"191-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0